Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
renin-angiotensin blockers + spironolactone
- Development stage
- Unknown
- Lead developer
- James A. Tumlin
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Renin-angiotensin (RAAS) blockers + spironolactone is a combination therapeutic regimen investigated for the treatment of Type 2 Diabetic Nephropathy. The regimen involves the use of maximal doses of RAAS inhibitors—either Angiotensin-Converting Enzyme (ACE) inhibitors like lisinopril or Angiotensin II Receptor Blockers (ARBs) like losartan—in conjunction with spironolactone, a steroidal mineralocorticoid receptor antagonist (MRA). The primary therapeutic objective is to achieve superior reduction in proteinuria and albuminuria and to slow the progression of chronic kidney disease (CKD) by more completely blocking the aldosterone escape phenomenon. Due to the high risk of hyperkalemia associated with dual RAAS and MRA blockade, clinical evaluation of this regimen (such as the MRA-ACE trial) often incorporates the use of potassium binders like patiromer to manage electrolyte imbalances.
- Other names
- MRA-ACEspironolactone + ACE inhibitorspironolactone + ARB
02
Targets
AR (Adrenergic receptors)AGTR1 (Angiotensin II Type-1 receptor)ACE (Angiotensin Converting Enzyme)GR (Glucocorticoid receptor)MR (Mineralocorticoid receptor)PPARG (Peroxisome proliferator-activated receptor gamma)PR (Progesterone receptor)REN (Renin)
Beyond the preview
Go deeper on renin-angiotensin blockers + spironolactone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on renin-angiotensin blockers + spironolactone.